Matinas BioPharma Investor Presentation Deck

21 In vitro Tumor Cell Inhibition with LNC Docetaxel Formulations RATIONALE AND NEXT STEPS ● ● LNC Docetaxel program also provides insight into tumor uptake of LNCs Foundation for subsequent small oligo work In vitro results demonstrate strong LNC efficacy in inhibiting tumor cell growth • In vivo studies planned in multiple tumor models % Inhibition 100 90 80 70 60 50 40 30 20 10 0 500 3 LNC Formulations Demonstrated Significantly Better Tumor Cell Inhibition Than Unformulated Drug MCF7 breast cancer cells COPYRIGHT MATINAS BIOPHARMA 250 MM-51 2024 125 MM-53 62 16 LNC-Docetaxel Dose (ng/well) MM-54 31 Taxol 8 4 MATINAS BIOPHARMA

View entire presentation